ClinicalTrials.gg
CompletedNCT03204682ENDOSTIMUpdated Nov 9, 2026

Repetitive Transcranial Magnetic Stimulation as an Analgesic Treatment in Endometriosis Chronic Pain : Feasibility

An interventional study of Repetitive transcranial magnetic stimulation in Deep Endometriosis and Chronic Pelvic Pain, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Apr 2016, registered Jun 2017).
Updated Nov 9, 2026Now CompletedResults publication added+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 128 studies in Endometriosis with a site in France — 51 open to participants now, 56 under way, 1 of them phase 3. Endometriosis · France.

Enrollment
60th of 70
24 · median 91
Started
2016
with 3 others
No phase
57 of 128
27 open now
Registered
24th of 128
by date
Lead sponsor
6 of 128
University Hospital, Clermont-Ferrand

Among the 128 studies in Endometriosis with a site in France, this one is the 60th largest by enrollment of the 70 interventional ones that give a count, is one of 4 that started in 2016, is one of 57 with no phase, and was the 24th registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

51 of the 128 studies in Endometriosis with a site in France are open now. Recruiting first, the newest first:

46 more — sign in →

All 51 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 55 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Endometriosis with a site in France, or all of them as a file.
02

Study summary

Endometriosis is associated with different types of pain (acute, chronic, excess nociception, neuropathic) generated by different mechanisms in the nervous system. The rTMS could provide significant analgesia for refractory endometriosis pain.

The aim of the study is to evaluate the feasibility of transcranial magnetic stimulation (rTMS) for analgesia on chronic refractory endometriosis pain.

Read the detailed description

The first step consists of the inclusion of 12 patients followed by the filling by each patient of the RedCap software of five simple numerical scales for 4 weeks . Realization of a brain and medullary MRI to allow neuronavigation. Realization of 5 sessions of rTMS in 5 days during the first week then evaluation (physical examination, questionnaires) in consultation on post-stimulation. Then followed for 28 days in total through self-assessment of pain that will be filled daily on REDCap and last consultation on D28 for further evaluation

03

Conditions studied

  • Deep Endometriosis
  • Chronic Pelvic Pain

Keywords

  • Endometriosis
  • Magnetic transcranial stimulation
  • Chronic pain
  • Analgesic
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Premenopausal (presence of at least one of the two ovaries and absence of clinical signs of menopause),
  • Not pregnant or breastfeeding;
  • At least one painful symptoms related to the existence of endometriosis (dyspareunia, dysmenorrhea, pain with defecation or urination, neuropathic pain);
  • Average VAS> 4/10, at least 4 days out of 7 for at least 3 months;
  • Hormonal treatment failure continued in association or not for pain control;
  • A level of understanding and satisfying expression in French;
  • Monitoring possible during the duration of the study (4 weeks).
  • These patients should be affiliated to the French social security and should have signed a written consent after receiving clear information.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with rTMS,
  • Industrial accident or notion of litigation
  • Cons-indication for rTMS (cortical lesion within 2cm of the motor cortex, ECT treatment during previous month, epilepsy and / or a history of epilepsy, history of head trauma, intracranial hypertension;
  • Metal clip; pacemaker,
  • Pregnant or breastfeeding women;
  • Pain lasting less than 3 months;
  • Another pain more severe than that associated with endometriosis;
  • Lack of filling of the computerized questionnaires on Redcap;
  • Incapable of understanding about ,
  • Patient under guardianship.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Patients with chronic refractory endometriosis pain

    The aim of the study is to evaluate the feasibility of transcranial magnetic stimulation (rTMS) for analgesia on chronic refractory endometriosis pain.

    Device: Repetitive transcranial magnetic stimulation

Interventions

  • DeviceRepetitive transcranial magnetic stimulation

    Realization of a brain and medullary MRI to allow neuronavigation. Realization of 5 sessions of rTMS in 5 days during the first week then evaluation (physical examination, questionnaires) in consultation on post-stimulation. Then followed for 28 days in total through self-assessment of pain that will be filled daily on REDCap and last consultation on D28 for further evaluation

06

What researchers measure

Primary outcomes

  1. Percentage of patients tolerant 5 sessions of stimulation and with no increase in pain

    The feasibility of rTMS treatment was defined if 7 patients or more over 12 tolerate the 5 sessions of stimulation showed no increase in pain

    Time frame: at day 8

Secondary outcomes

  1. Change in pain between the mean pain evaluated before inclusion

    thanks to the visual analogue scale traded between 0 and 100

    Time frame: at day 8

  2. Endometriosis Health Profile Questionnaire (EPH-30);

    Variation in scores of questionnaires before and after stimulation

    Time frame: at day 8

  3. Brief Pain Inventory (BPI): digital

    Variation in scores of questionnaires before and after stimulation

    Time frame: at day 8

  4. Beck Questionnaire (Depression)

    Variation in scores of questionnaires before and after stimulation

    Time frame: at day 8

  5. STAI of Anxiety Scale; Scale of alexythymie of Toronto

    Variation in scores of questionnaires before and after stimulation

    Time frame: at day 8

  6. Catastrophizing Pain Scale (personality)

    Variation in scores of questionnaires before and after stimulation

    Time frame: at day 8

  7. Quality of Life Questionnaire SF-36

    Variation in scores of questionnaires before and after stimulation

    Time frame: at day 8

  8. Migraine criteria (ICHD3)

    Variation in scores of questionnaires before and after stimulation

    Time frame: at day 8

  9. Gastrointestinal quality of Life Index (GICLI)

    Variation in scores of questionnaires before and after stimulation

    Time frame: at day 8

07

Study locations

1 site
  • CHU de Clermont-Ferrand
    Clermont-Ferrand, Auvergne 63003, France
08

References and documents

Publications

  • Pinot-Monange A, Moisset X, Chauvet P, Gremeau AS, Comptour A, Canis M, Pereira B, Bourdel N. Repetitive Transcranial Magnetic Stimulation Therapy (rTMS) for Endometriosis Patients with Refractory Pelvic Chronic Pain: A Pilot Study. J Clin Med. 2019 Apr 13;8(4):508. doi: 10.3390/jcm8040508. PubMed 31013910 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Aug 2017, 16 months.

Of 199 non-industry interventional studies with no phase under Endometriosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 44. This study's 16 months is below that.

Counting every sponsor, half of 214 studies reached it within 25 months; a quarter within 13 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Apr 2018 → Aug 2017 and completion May 2018 → Apr 2018.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2017
First posted
Jul 2, 2017
StartActual
Apr 13, 2016
Primary completionActual
Aug 21, 2017was Apr 2018
CompletionActual
Apr 13, 2018was May 2018
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 9, 2026
Primary completion
Apr 2018→Aug 21, 2017 (actual)
Nov 9, 2026
Study completion
May 2018→Apr 13, 2018 (actual)
Nov 9, 2026
Publications
Results publication added: Pinot-Monange A, Moisset X, Chauvet P, Gremeau AS, Comptour A, Canis M, Pereira B, Bourdel N. Repetitive Transcranial Magnetic Stimulation Therapy (rTMS) for E… PubMed 31013910 ↗
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Status unknown→Completed
    Publications Results publication added: Pinot-Monange A, Moisset X, Chauvet P, Gremeau AS, Comptour A, Canis M, Pereira B, Bourdel N. Repetitive Transcranial Magnetic Stimulation Therapy (rTMS) for E… PubMed 31013910 ↗
    Primary completion Apr 2018→Aug 21, 2017 (now actual)
    Study completion May 2018→Apr 13, 2018 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03204682
Responsible party
Sponsor
First posted
Jul 2, 2017
Start date
Apr 13, 2016
Primary completion
Aug 21, 2017
Completion
Apr 13, 2018
Last update
Nov 9, 2026

Study contacts

Nicolas BOURDEL, PH
principal investigator · University Hospital, Clermont-Ferrand

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion